Search

Your search keyword '"Vermorken, J."' showing total 886 results
Start Over Author "Vermorken, J."
886 results on '"Vermorken, J."'

1. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

Author

Opdam, M., van der Noort, V., Kleijn, M., Glas, A., Mandjes, I., Kleiterp, S., Hilbers, F. S., Kruger, D. T., Bins, A. D., de Jong, P. C., Schiphorst, P. P. J. B. M., van Dalen, T., Flameling, B., Rietbroek, R. C., Beeker, A., van den Heiligenberg, S. M., Bakker, S. D., Wymenga, A. N. M., Oving, I. M., Bijlsma, R. M., van Diest, P. J., Vermorken, J. B., van Tinteren, H., and Linn, S. C.

Published
2022
Full Text
View/download PDF

2. Lenvatinib ± Pembrolizumab Versus Chemotherapy for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That Progressed after Platinum and Immunotherapy: The Phase 2 LEAP-009 Study

Author

Harrington, K., primary, Kim, H.R., additional, Salas, S., additional, Oliva, M., additional, Metcalf, R., additional, Bernsdorf, M., additional, Kim, J.W., additional, Cohen, E., additional, Siu, L.L., additional, Rischin, D., additional, Licitra, L., additional, Vermorken, J., additional, Le, Q.T., additional, Tahara, M., additional, Machiels, J.P., additional, O'Hara, K., additional, Pathiraja, K., additional, Gumuscu, B., additional, Bidadi, B., additional, and Burtness, B., additional

Published
2024
Full Text
View/download PDF

3. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Adelstein, D.J., Agarwal, J., Alfonsi, M., Argiris, A., Aupérin, A., Bacigalupo, A., Bar-Ad, V., Bartelink, H., Beadle, B., Belkacemi, Y., Bensadoun, R.J., Bernier, J., Blanchard, P., Bourhis, J., Bratland, Å., Brizel, D., Budach, V., Budach, W., Burtness, B., Calais, G., Campbell, B., Caudell, J., Chabaud, S., Chamorey, E., Chaukar, D., Cheugoua-Zanetsie, M., Cho, K.H., Choussy, O., Cruz Hernandez, J.J., Denham, J.W., Dobrowsky, W., Dominello, M.M, Driessen, C.M.L., Fallai, C., Forastiere, A.A., Fortpied, C., Fountzilas, G., Garaud, P., Garden, A.S., Gery, B., Ghadjar, P., Ghi, M.G., Ghosh Laskar, S., Graff-Cailleaud, P., Grau, C., Gregoire, V., Hackshaw, A., Haddad, E, Haffty, B.G., Hansen, A., Hay, J.H., Hayoz, S., Horiot, J.C., Hitt, R., Jeremic, B., Johansen, J., Jones, C., Julieron, M., Kristensen, C.A., Kumar, S., Lacas, B., Langendijk, J.A., Lapeyre, M., Lartigau, E., Licitra, L., Le, Q.T., Lee, J.W., Lee, P., Lewin, F., Li, Y., Lopes, A., Lotayef, M., Maciejewski, B., Mazeron, J.J., Mehta, S., Michalski, W., Moon, J., Moon, S.H., Moyal, E., Nankivell, M., Nilsson, P., Olmi, P., Orecchia, R., O'Sullivan, B., Overgaard, J., Parmar, M.K.B., Petit, C., Pignon, J.P., Pointreau, Y., Posner, M.R., Poulsen, M.G., Quon, H., Racadot, S., Rosenthal, D.I., Rovea, P., Ruo Redda, M.G., Sanguineti, G., Shenouda, G., Simes, J., Sharma, A., Simon, C., Sire, C., Skladowski, K., Spencer, S., Staar, S., Strojan, P., Stromberger, C., Suwinski, R., Szutkowski, Z., Takácsi-Nagy, Z., Tao, Y.G., Temam, S., Thomson, D., Tobias, J.S., Torres-Saavedra, P., Torri, V., Tripcony, L., Trotti, A., Tseroni, V., van Herpen, C., van Tinteren, H., Vermorken, J., Viegas, C.M.P., Vokes, E.E., Waldron, J., Wernecke, K.D, Widder, J., Wolf, G.T., Wong, S.J., Wu, J.S., Yamazaki, H., Zaktonik, B., Zackrisson, B., Zhong, L.P., Petit, Claire, Lacas, Benjamin, Pignon, Jean-Pierre, Le, Quynh Thu, Grégoire, Vincent, Grau, Cai, Hackshaw, Allan, Zackrisson, Björn, Parmar, Mahesh K B, Lee, Ju-Whei, Ghi, Maria Grazia, Sanguineti, Giuseppe, Temam, Stéphane, Cheugoua-Zanetsie, Maurice, O'Sullivan, Brian, Posner, Marshall R, Vokes, Everett E, Cruz Hernandez, Juan J, Szutkowski, Zbigniew, Lartigau, Eric, Budach, Volker, Suwiński, Rafal, Poulsen, Michael, Kumar, Shaleen, Ghosh Laskar, Sarbani, Mazeron, Jean-Jacques, Jeremic, Branislav, Simes, John, Zhong, Lai-Ping, Overgaard, Jens, Fortpied, Catherine, Torres-Saavedra, Pedro, Bourhis, Jean, Aupérin, Anne, and Blanchard, Pierre

Published
2021
Full Text
View/download PDF

4. Maligne aandoeningen

Author

van Rijswijk, R. E. N., Schellens, J. H. M., Vermorken, J. B., van der Vijgh, W. J. F., Cohen, A. F., editor, Danhof, M., editor, de Greef, H. J. M. M., editor, Ijzerman, A. P., editor, Kenter, M. J. H., editor, Schellens, J. H. M., editor, and Sitsen, J. M. A., editor

Published
2017
Full Text
View/download PDF

5. MO-0717 Seasonality of radiotherapy efficacy for head & neck cancer patients: MACH-NC/MARCH meta-analyses

Author

Blanchard, P., primary, Lacas, B., additional, Bourhis, J., additional, Limkin, E., additional, Parmar, M., additional, Licitra, L., additional, Le, Q., additional, Fortpied, C., additional, Langendijk, J., additional, Vermorken, J., additional, Bernier, J., additional, Trotti, A., additional, Overgaard, J., additional, Harris, J., additional, Pignon, J., additional, and Aupérin, A., additional

Published
2023
Full Text
View/download PDF

6. Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 phase II study

Author

Tryfonidis, Konstantinos, Marreaud, S., Khaled, H., De Valk, B., Vermorken, J., Welnicka-Jaskiewicz, M., Aalders, K., Bartlett, J. M. S., Biganzoli, L., Bogaerts, J., Cameron, David, and On behalf of the EORTC- Breast Cancer Group

Published
2017
Full Text
View/download PDF

7. Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature

Author

MS CGO, MS Medische Oncologie, Cancer, Pathologie, Opdam, M, van der Noort, V, Kleijn, M, Glas, A, Mandjes, I, Kleiterp, S, Hilbers, F S, Kruger, D T, Bins, A D, de Jong, P C, Schiphorst, P P J B M, van Dalen, T, Flameling, B, Rietbroek, R C, Beeker, A, van den Heiligenberg, S M, Bakker, S D, Wymenga, A N M, Oving, I M, Bijlsma, R M, van Diest, P J, Vermorken, J B, van Tinteren, H, Linn, S C, MS CGO, MS Medische Oncologie, Cancer, Pathologie, Opdam, M, van der Noort, V, Kleijn, M, Glas, A, Mandjes, I, Kleiterp, S, Hilbers, F S, Kruger, D T, Bins, A D, de Jong, P C, Schiphorst, P P J B M, van Dalen, T, Flameling, B, Rietbroek, R C, Beeker, A, van den Heiligenberg, S M, Bakker, S D, Wymenga, A N M, Oving, I M, Bijlsma, R M, van Diest, P J, Vermorken, J B, van Tinteren, H, and Linn, S C

Published
2022

8. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer

Author

Cohen, E. E. W., Licitra, L. F., Burtness, B., Fayette, J., Gauler, T., Clement, P. M., Grau, J. J., del Campo, J. M., Mailliez, A., Haddad, R. I., Vermorken, J. B., Tahara, M., Guigay, J., Geoffrois, L., Merlano, M. C., Dupuis, N., Krämer, N., Cong, X. J., Gibson, N., Solca, F., Ehrnrooth, E., and Machiels, J.-P. H.

Published
2017
Full Text
View/download PDF

10. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study

Author

Psyrri, A., Fortpied, C., Koutsodontis, G., Avgeris, M., Kroupis, C., Goutas, N., Menis, J., Herman, L., Giurgea, L., Remenár, É., Degardin, M., Pateras, I. S., Langendijk, J. A., van Herpen, C. M. L., Awada, A., Germà-Lluch, J. R., Kienzer, H. R., Licitra, L., and Vermorken, J. B.

Published
2017
Full Text
View/download PDF

11. Phase 2 LEAP-009: Lenvatinib (Lenva) With or Without Pembrolizumab (Pembro) vs. Chemotherapy (Chemo) for Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) That has Progressed on Platinum and Immunotherapy

Author

Harrington, K., primary, Cohen, E., additional, Siu, L., additional, Rischin, D., additional, Licitra, L., additional, Vermorken, J., additional, Le, Q.T., additional, Tahara, M., additional, Machiels, J.P., additional, Hawk, N., additional, Ge, J., additional, Bidadi, B., additional, Swaby, R., additional, and Burtness, B., additional

Published
2022
Full Text
View/download PDF

14. Clinical Pharmacology of Carboplatin Administered in Alternating Sequence with Paclitaxel in Patients with Non-Small Cell Lung Cancer: A European Cancer Centre (ECC) Study

Author

van Warmerdam, L. J. C., Huizing, M. T., Giaccone, G., Bakker, P. J. M., Vermorken, J. B., Postmus, P. E., van Zandwijk, N., Koolen, M. G. J., ten Bokkel Huinink, W. W., Maes, R. A. A., van der Vijgh, W. J. F., Veenhof, C. H. N., Beijnen, J. H., Pinedo, H. M., editor, and Schornagel, J. H., editor

Published
1996
Full Text
View/download PDF

30. Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis

Author

Petit, Claire, primary, Lacas, Benjamin, additional, Pignon, Jean-Pierre, additional, Le, Quynh Thu, additional, Grégoire, Vincent, additional, Grau, Cai, additional, Hackshaw, Allan, additional, Zackrisson, Björn, additional, Parmar, Mahesh K B, additional, Lee, Ju-Whei, additional, Ghi, Maria Grazia, additional, Sanguineti, Giuseppe, additional, Temam, Stéphane, additional, Cheugoua-Zanetsie, Maurice, additional, O'Sullivan, Brian, additional, Posner, Marshall R, additional, Vokes, Everett E, additional, Cruz Hernandez, Juan J, additional, Szutkowski, Zbigniew, additional, Lartigau, Eric, additional, Budach, Volker, additional, Suwiński, Rafal, additional, Poulsen, Michael, additional, Kumar, Shaleen, additional, Ghosh Laskar, Sarbani, additional, Mazeron, Jean-Jacques, additional, Jeremic, Branislav, additional, Simes, John, additional, Zhong, Lai-Ping, additional, Overgaard, Jens, additional, Fortpied, Catherine, additional, Torres-Saavedra, Pedro, additional, Bourhis, Jean, additional, Aupérin, Anne, additional, Blanchard, Pierre, additional, Adelstein, D.J., additional, Agarwal, J., additional, Alfonsi, M., additional, Argiris, A., additional, Aupérin, A., additional, Bacigalupo, A., additional, Bar-Ad, V., additional, Bartelink, H., additional, Beadle, B., additional, Belkacemi, Y., additional, Bensadoun, R.J., additional, Bernier, J., additional, Blanchard, P., additional, Bourhis, J., additional, Bratland, Å., additional, Brizel, D., additional, Budach, V., additional, Budach, W., additional, Burtness, B., additional, Calais, G., additional, Campbell, B., additional, Caudell, J., additional, Chabaud, S., additional, Chamorey, E., additional, Chaukar, D., additional, Cheugoua-Zanetsie, M., additional, Cho, K.H., additional, Choussy, O., additional, Cruz Hernandez, J.J., additional, Denham, J.W., additional, Dobrowsky, W., additional, Dominello, M.M, additional, Driessen, C.M.L., additional, Fallai, C., additional, Forastiere, A.A., additional, Fortpied, C., additional, Fountzilas, G., additional, Garaud, P., additional, Garden, A.S., additional, Gery, B., additional, Ghadjar, P., additional, Ghi, M.G., additional, Ghosh Laskar, S., additional, Graff-Cailleaud, P., additional, Grau, C., additional, Gregoire, V., additional, Hackshaw, A., additional, Haddad, E, additional, Haffty, B.G., additional, Hansen, A., additional, Hay, J.H., additional, Hayoz, S., additional, Horiot, J.C., additional, Hitt, R., additional, Jeremic, B., additional, Johansen, J., additional, Jones, C., additional, Julieron, M., additional, Kristensen, C.A., additional, Kumar, S., additional, Lacas, B., additional, Langendijk, J.A., additional, Lapeyre, M., additional, Lartigau, E., additional, Licitra, L., additional, Le, Q.T., additional, Lee, J.W., additional, Lee, P., additional, Lewin, F., additional, Li, Y., additional, Lopes, A., additional, Lotayef, M., additional, Maciejewski, B., additional, Mazeron, J.J., additional, Mehta, S., additional, Michalski, W., additional, Moon, J., additional, Moon, S.H., additional, Moyal, E., additional, Nankivell, M., additional, Nilsson, P., additional, Olmi, P., additional, Orecchia, R., additional, O'Sullivan, B., additional, Overgaard, J., additional, Parmar, M.K.B., additional, Petit, C., additional, Pignon, J.P., additional, Pointreau, Y., additional, Posner, M.R., additional, Poulsen, M.G., additional, Quon, H., additional, Racadot, S., additional, Rosenthal, D.I., additional, Rovea, P., additional, Ruo Redda, M.G., additional, Sanguineti, G., additional, Shenouda, G., additional, Simes, J., additional, Sharma, A., additional, Simon, C., additional, Sire, C., additional, Skladowski, K., additional, Spencer, S., additional, Staar, S., additional, Strojan, P., additional, Stromberger, C., additional, Suwinski, R., additional, Szutkowski, Z., additional, Takácsi-Nagy, Z., additional, Tao, Y.G., additional, Temam, S., additional, Thomson, D., additional, Tobias, J.S., additional, Torres-Saavedra, P., additional, Torri, V., additional, Tripcony, L., additional, Trotti, A., additional, Tseroni, V., additional, van Herpen, C., additional, van Tinteren, H., additional, Vermorken, J., additional, Viegas, C.M.P., additional, Vokes, E.E., additional, Waldron, J., additional, Wernecke, K.D, additional, Widder, J., additional, Wolf, G.T., additional, Wong, S.J., additional, Wu, J.S., additional, Yamazaki, H., additional, Zaktonik, B., additional, Zackrisson, B., additional, and Zhong, L.P., additional

Published
2021
Full Text
View/download PDF

32. De-escalation after DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup framework for future de-escalation studies

Author

Mehanna, H. Rischin, D. Wong, S.J. Gregoire, V. Ferris, R. Waldron, J. Le, Q.-T. Forster, M. Gillison, M. Laskar, S. Tahara, M. Psyrri, A. Vermorken, J. Porceddu, S.

Abstract

Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is increasing rapidly. The younger age, significantly improved prognosis, and relative morbidity of the standard-of-care cisplatin and radiotherapy in this population have led to the popularization of the concept of treatment de-escalation. The recent results of the first 3 randomized de-escalation trials, however, have shown a clear detriment in survival when cisplatin is omitted or substituted. In view of these results, the Head and Neck Cancer International Group identified the need to issue guidance regarding future de-escalation studies for patients with HPV-positive head and neck cancer to avoid the possibility of patients being harmed. We review the current state of the literature regarding HPV de-escalation trials and present a framework and guidance on future and existing clinical trials for treatment de-escalation of HPV-positive OPC. De-escalation paradigms of HPV-positive OPC should be evaluated in phase II studies, and results should be awaited before proceeding to phase III studies. Implementation into clinical practice before high-level evidence is available should not be undertaken in this context. Finally, harm-minimization techniques should also be evaluated as an alternative to de-escalation of treatment in these patient groups. © 2020 by American Society of Clinical Oncology Licensed under the Creative Commons Attribution 4.0 License

Published
2020

33. De-Escalation After DE-ESCALATE and RTOG 1016: A Head and Neck Cancer InterGroup Framework for Future De-Escalation Studies

Author

Mehanna, H, Rischin, D, Wong, SJ, Gregoire, V, Ferris, R, Waldron, J, Le, Q-T, Forster, M, Gillison, M, Laskar, S, Tahara, M, Psyrri, A, Vermorken, J, Porceddu, S, Mehanna, H, Rischin, D, Wong, SJ, Gregoire, V, Ferris, R, Waldron, J, Le, Q-T, Forster, M, Gillison, M, Laskar, S, Tahara, M, Psyrri, A, Vermorken, J, and Porceddu, S

Abstract

Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC) is increasing rapidly. The younger age, significantly improved prognosis, and relative morbidity of the standard-of-care cisplatin and radiotherapy in this population have led to the popularization of the concept of treatment de-escalation. The recent results of the first 3 randomized de-escalation trials, however, have shown a clear detriment in survival when cisplatin is omitted or substituted. In view of these results, the Head and Neck Cancer International Group identified the need to issue guidance regarding future de-escalation studies for patients with HPV-positive head and neck cancer to avoid the possibility of patients being harmed. We review the current state of the literature regarding HPV de-escalation trials and present a framework and guidance on future and existing clinical trials for treatment de-escalation of HPV-positive OPC. De-escalation paradigms of HPV-positive OPC should be evaluated in phase II studies, and results should be awaited before proceeding to phase III studies. Implementation into clinical practice before high-level evidence is available should not be undertaken in this context. Finally, harm-minimization techniques should also be evaluated as an alternative to de-escalation of treatment in these patient groups.

Published
2020

34. PEMBROLIZUMAB PLUS LENVATINIB VS CHEMOTHERAPY AND LENVATINIB MONOTHERAPY FOR RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA THAT PROGRESSED ON PLATINUM THERAPY AND IMMUNOTHERAPY: LEAP-009

Author

Harrington, K, Cohen, E, Siu, L, Rischin, D, Licitra, L, Vermorken, J, Quynh-Thu, L, Tahara, M, Machiels, J-P, Hawk, N, Ge, J, Bidadi, B, Swaby, R, Burtness, B, Harrington, K, Cohen, E, Siu, L, Rischin, D, Licitra, L, Vermorken, J, Quynh-Thu, L, Tahara, M, Machiels, J-P, Hawk, N, Ge, J, Bidadi, B, Swaby, R, and Burtness, B

Abstract

Background Pembrolizumab alone and in combination with platinum-based chemotherapy have become standard first-line treatment options for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), and there is a growing unmet need for safe and efficacious treatment options for R/M HNSCC that has progressed on or after platinum-based chemotherapy and immunotherapy. Data from Study 111/KEYNOTE-146 showed promising antitumor activity and acceptable safety for the PD-1 inhibitor pembrolizumab given in combination with the multikinase inhibitor lenvatinib in patients with metastatic HNSCC.1 LEAP-009 (NCT04428151), a global, randomized, open-label, phase 2 trial, will assess the efficacy and safety of pembrolizumab in combination with lenvatinib versus SOC chemotherapy, as well as the efficacy and safety of lenvatinib monotherapy, in patients with R/M HNSCC that has progressed after platinum-based chemotherapy and a PD-(L)1 inhibitor. Methods Eligible patients are adults with histologically confirmed, locally incurable R/M HNSCC of the oral cavity, oropharynx, hypopharynx, or larynx, disease progression at any time during or after platinum-containing chemotherapy (with or without cetuximab), disease progression within 12 weeks from the last dose of treatment with ≥2 doses of a PD-(L)1 inhibitor, measurable disease based on RECIST v1.1 as confirmed by BICR, ECOG performance status of 0 or 1, and no major blood vessel invasion/infiltration. Patients will be randomized 3:3:2 to pembrolizumab (200 mg IV Q3W for up to 35 cycles) plus lenvatinib (20 mg orally once daily), investigator’s choice of SOC chemotherapy (docetaxel, paclitaxel, cetuximab, or capecitabine), or lenvatinib monotherapy (24 mg orally once daily). Randomization will be stratified by PD-L1 tumor proportion score (<50% versus ≥50%) and ECOG performance status (0 versus 1). Treatment will continue until centrally verified disease progression, unacceptable toxicity, or decision to withdraw. Patien

Published
2020

35. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group

Author

Lacas, Benjamin, primary, Carmel, Alexandra, additional, Landais, Cécile, additional, Wong, Stuart J., additional, Licitra, Lisa, additional, Tobias, Jeffrey S., additional, Burtness, Barbara, additional, Ghi, Maria Grazia, additional, Cohen, Ezra E.W., additional, Grau, Cai, additional, Wolf, Gregory, additional, Hitt, Ricardo, additional, Corvò, Renzo, additional, Budach, Volker, additional, Kumar, Shaleen, additional, Laskar, Sarbani Ghosh, additional, Mazeron, Jean-Jacques, additional, Zhong, Lai-Ping, additional, Dobrowsky, Werner, additional, Ghadjar, Pirus, additional, Fallai, Carlo, additional, Zakotnik, Branko, additional, Sharma, Atul, additional, Bensadoun, René-Jean, additional, Ruo Redda, Maria Grazia, additional, Racadot, Séverine, additional, Fountzilas, George, additional, Brizel, David, additional, Rovea, Paolo, additional, Argiris, Athanassios, additional, Nagy, Zoltán Takácsi, additional, Lee, Ju-Whei, additional, Fortpied, Catherine, additional, Harris, Jonathan, additional, Bourhis, Jean, additional, Aupérin, Anne, additional, Blanchard, Pierre, additional, Pignon, Jean-Pierre, additional, Adelstein, D.J., additional, Alfonsi, M., additional, Belkacemi, Y., additional, Bar-Ad, V., additional, Bernier, J., additional, Bratland, Å., additional, Calais, G., additional, Campbell, B., additional, Caudell, J., additional, Chabaud, S., additional, Chamorey, E., additional, Chaukar, D., additional, Choi, K.N., additional, Choussy, O., additional, Collette, L., additional, Cruz, J.J., additional, Dani, C., additional, Dauzier, E., additional, Forastiere, A.A., additional, Garaud, P., additional, Gregoire, V., additional, Hackshaw, A., additional, Haddad, E., additional, Haffty, B.G., additional, Hansen, A., additional, Hayoz, S., additional, Horiot, J.C., additional, Jeremic, B., additional, Karrison, T.G., additional, Langendijk, J.A., additional, Lapeyre, M., additional, Lartigau, E., additional, Leong, T., additional, Le, Q.T., additional, Lee, P.P.Y., additional, Lewin, F., additional, Lin, A., additional, Lopes, A., additional, Mehta, S., additional, Moon, J., additional, Moyal, E., additional, Occéan, B.V., additional, Olmi, P., additional, Orecchia, R., additional, O'Sullivan, B., additional, Overgaard, J., additional, Petit, C., additional, Quon, H., additional, Sanguineti, G., additional, Satar, T., additional, Simes, J., additional, Simon, C., additional, Sire, C., additional, Staar, S., additional, Stromberger, C., additional, Strojan, P., additional, Temam, S., additional, Thomson, D., additional, Timochenko, A., additional, Torri, V., additional, Tseroni, V., additional, Vermorken, J., additional, Vokes, E.E., additional, Waldron, J., additional, Wernecke, K.D., additional, Widder, J., additional, and Zackrisson, B., additional

Published
2021
Full Text
View/download PDF

36. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)

Author

du Bois, A., Quinn, M., Thigpen, T., Vermorken, J., Avall-Lundqvist, E., Bookman, M., Bowtell, D., Brady, M., Casado, A., Cervantes, A., Eisenhauer, E., Friedlaender, M., Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Hogberg, T., Kaye, S., Kitchener, H., Kristensen, G., Mannel, R., Meier, W., Miller, B., Neijt, J. P., Oza, A., Ozols, R., Parmar, M., Pecorelli, S., Pfisterer, J., Poveda, A., Provencher, D., Pujade-Lauraine, E., Randall, M., Rochon, J., Rustin, G., Sagae, S., Stehman, F., Stuart, G., Trimble, E., Vasey, P., Vergote, I., Verheijen, R., and Wagner, U.

Published
2005

37. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration

Author

Stuart, G., Avall-Lundqvist, E., du Bois, A., Bookman, M., Bowtell, D., Brady, M., Casado, A., Cervantes, A., Eisenhauer, E., Friedlaender, M., Fujiwara, K., Grenman, S., Guastalla, J. P., Harper, P., Hogberg, T., Kaye, S., Kitchener, H., Kristensen, G., Mannel, R., Meier, W., Miller, B., Oza, A., Ozols, R., Parmar, M., Pfisterer, J., Poveda, A., Provencher, D., Pujade-Lauraine, E., Quinn, M., Randall, M., Rochon, J., Rustin, G., Sagae, S., Stehman, F., Trimble, E., Thigpen, T., Vasey, P., Vergote, I., Verheijen, R., Vermorken, J., and Wagner, U.

Published
2005

43. Hoofd-halstumoren

Author

Roodenburg, J. L. N., primary, de Jong, R. J. Baatenburg, additional, Reintsema, H., additional, van Laer, C. G., additional, Langendijk, J. A., additional, Vermeersch, H., additional, and Vermorken, J. B., additional

Published
2011
Full Text
View/download PDF

44. Diagnostiek in de oncologie

Author

Vermorken, J. B., primary, Schrijvers, D. L. A. L., additional, Weyler, J. J. J., additional, Moreels, T., additional, Carp, L. W. G., additional, Barentsz, J., additional, and Heijmink, S. W. T. P. J., additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results